Diabetes drugs may slow the progression of Parkinson's disease

File photo: University of Warwick's affected dopamine-energy neuron cells accumulate a special protein called α synth nucleoprotein, which forms a Louis small structure, where levels are directly related to the severity of the disease, and α synth nucleoproteins in the early stages of aggregation produce a series of toxic effects that many event researchers do not know about.
in this study, entitled "Alpha-synuclein aggregates increased conductance of substantia nigra dopamine neurons, an effect partly reversed by the KATP channel resedor glibenclamide", the researchers found that by introducing a low-concentration structure-determined α synaptic nucleoprotein aggregate into a single dopamine neuron, the cell membrane's channels are turned on, greatly reducing the neurotic excitability of the cell membrane.
researcher Emily Hill says that by injecting low-concentration structurally determined α synth nucleoprotein aggregates into a single dopamine-energy neuron, we can analyze the properties of early changes in neuron function, which usually occur before the early clinical stages of the disease.
we have observed that by opening the membrane channel of the cell, the neuron's excitability is significantly reduced, and if we can block the channel, we may be able to block the production of early toxic effects.
There is research evidence that the open membrane channel is a type of channel called the KATP channel, which can be blocked by some of the anti-diabetic drugs currently in use, and the researchers note that we were surprised to find that the anti-diabetic drug glibenclamide significantly reduces the effects of α synaptic nucleoprotein aggregates.
Finally, researcher Emily added that the drugs currently used can be redirected to treat many different human diseases, and we know that people with type 2 diabetes tend to have a lower incidence of Parkinson's disease, while understanding the molecular mechanisms behind the occurrence of α synactical nucleoprotein pathology in a single brain neuron cell may help develop new targeted therapies for Parkinson's disease.
original source: E. Hill, R. Gowers, M. J. E. Richardson, M. J. Wall. Alpha-synuclein aggregates increase the conductance of substantia nigra dopamine neurons, an effect partly reversed by the KATP channel inhibitor glibenclamide, eneuro (2020). DOI:10.1523/ENEURO.0330-20.2020。